Plasmid Inhalation: Delivery to the Airways. (2005)

L. A. Davies, S. C. Hyde and D. R. Gill

DNA Pharmaceuticals, 145-164 (3-527-31187-4)

Wiley   Back to Book Chapters

Gene transfer to the airways is being investigated as a possible therapy for a variety of acute and chronic lung diseases such as cancer, cystic fibrosis and emphysema. Lung gene transfer is also being developed for applications such as the prevention of lung transplant rejection and the treatment of lung damage following radiotherapy. The lung is a complex organ containing multiple cell types. The tracheobronchial tree extends from the trachea down through numerous divisions of airways lined with epithelium. In the larger airways the epithelium is pseudostratified, consisting mainly of ciliated and non-ciliated columnar cells, goblet cells and a layer of basal cells; the epithelium eventually transitions to a single layer of cells lining the respiratory bronchioles. The parenchyma of the lung contains the gas-exchanging alveolar cells and is highly vascularized with capillary endothelial cells. Therapeutic gene transfer will require gene expression in the appropriate cell types of the lung, which can be achieved by judicious selection of the gene transfer agent (GTA). Viral vectors transduce cells depending on receptor specificity and availability for uptake, although this may be modified by manipulation of the virus pseudotype. Following gene transfer to the lung, several viral GTAs have resulted in debilitating immune and inflammatory responses limiting the options for repeated administration of these vectors. Recently there has been increased interest in the use of non-viral, plasmid-based GTAs that can be manipulated to transfect a wide range of lung cell types. In addition to the use of naked plasmid DNA (pDNA), plasmids may also be complexed with a variety of lipids, polymers and polycations and many of these have been evaluated following delivery to the lung.

Home
News
Introductory Videos
Medical Futures Innovation Award 2011
Twitter Feed
About Us
Contact Us
Careers
Resources
Lab Events
Environemental Policy
About this Site

Google Site Search

Site Feedback Form

All Site Images

 

UK CFGTC

How the Consortium works/FAQs

Consortium Website

Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial

Milestones

GL67A/pGM169

The Run-in Study

Single Dose Clinical Trial

Multi Dose Clinical Trial

 

Our Research

Non-viral Vector Development

Aerosol Mediated Gene Delivery

Viral Vector Development

Taqman Core Facility

Cystic Fibrosis

History of CF

Discovery of the CFTR Gene

CFTR Protein Structure

CFTR Function

CF Links

 

Gene Therapy

Introduction to Gene Therapy

Other CF Gene Therapy Groups

Why use Gene Therapy for CF

Target Cells for CF Gene Therapy

Barriers for CF Gene Therapy

Clinical Trials

Gene Therapy Successes

Gene Therapy Links

 

 

Publications

Papers in Journals

Conference Posters & Presentations

Book Chapters

D.Phil Theses

Lectures

 

Gene Therapy Seminars

Schedule

Directions & Venue